Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 99, Issue 2, 2013, Pages

  Fujimoto, Kanta ^a   Hamamoto, Yoshiyuki ^a   Honjo, Sachiko ^a   Kawasaki, Yukiko ^a   Mori, Kanako ^a   Tatsuoka, Hisato ^a   Matsuoka, Atsuko ^a   Wada, Yoshiharu ^a   Ikeda, Hiroki ^a   Fujikawa, Jun ^a   Koshiyama, Hiroyuki ^a,b  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Pioglitazone; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; PIOGLITAZONE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BODY MASS; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RETROSPECTIVE STUDY; SMOKING; TREATMENT DURATION;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84876735310     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.11.013     Document Type: Article

References (10)

1. Lewis J.D., Ferrara A., Peng T., Hedderson M., Bilker W.B., Quesenberry C.P., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
2. Neumann A., Weill A., Ricordeau P., Fagot J.P., Alla F., Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012, 55:1953-1962.
3. Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information 2009, Available from, [June 2012]. http://www.actos.com/.
4. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
5. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
6. Zhu Z., Shen Z., Lu Y., Zhong S., Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012, 98:159-163.
7. Food and Drug Administration FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure 2012, Available from, [June 2012]. http://www.fda.gov/Drugs/DrugSafety/ucm226214/.
8. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34:1369-1371.
9. Tseng C.H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012, 35:278-280.
10. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004, 43:993-1002.